When we reverse type 2 diabetes, hyperinsulinemia, and obesity, we are advocating for less medical intervention and more patient self-care.
Empowering the patient to manage a lifestyle disease with a lifestyle intervention does not result in a medical profit.
There is no financial incentive in the Business of Medicine, Big Pharma, or Big Food for this position.
It is obvious that big pharma and big food will not likely be supporting studies that reduce the utilization of their products over non-compensable lifestyle changes. Evidence-based academic research is also unlikely to be performed by academicians who are funded by these same interests. The entire health delivery industry seems to be geared towards medicalization of treatment rather than lifestyle improvement, which would radically disrupt the status quo. “doctors who got money from drug and device makers—even just a meal—prescribed a higher percentage of brand-name drugs overall than doctors who didn’t” and “the more money doctors receive…the more brand-name drugs they tend to prescribe.” Ornstein C, Jones RG, Tigas M. Now there’s proof: docs who get company cash tend to prescribe more brand-name meds. ProPublica. https://www.propublica.org/article/doctors-who-take-company-cash-tend-to-prescribe-more-brand-name-drugs. Published March 17, 2016. Accessed May 1, 2016.
The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. J P Orlowski and L Wateska. Chest 1992;102; 270-273 DOI 10.1378/chest.102.1.270Tags: Business of Medicine, Diabetes, Hyperinsulinemia, pharmaceutical